Kidney Cancer benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Cabozantinib Effective in Treating Metastatic Kidney Cancer by Angela Mohan on February 15, 2021 at 3:21 PM
Cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer, as per results of a SWOG Cancer Research Network trial.
These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium 2021. The findings will be simultaneously published in
The Lancet.
There are currently no effective treatments for metastatic papillary kidney cancer, or metastatic pRCC, a rare subtype of kidney cancer. One study of 38 patients found that the average survival rate was eight months after diagnosis.
Sumanta Pal, MD, clinical professor of medical oncology at City of Hope, a comprehensive cancer center, and an investigator at SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), said there is hope for metastatic papillary kidney cance
Study reveals cabozantinib most effective treatment for metastatic papillary kidney cancer ANI | Updated: Feb 14, 2021 11:12 IST
Washington [US], February 14 (ANI): In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice.
These findings were published in The Lancet.
There are currently no effective treatments for metastatic papillary kidney cancer, or metastatic pRCC, a rare subtype of kidney cancer. One study of 38 patients found that the average survival rate was eight months after diagnosis.
– Results of phase 2 trial show CABOMETYX significantly improved progression-free survival versus current guideline-preferred therapy –
– Data to be presented during the 2021. | February 16, 2021
® (cabozantinib) compared with sunitinib, the current preferred therapy according to U.S. cancer treatment guidelines,
1 in patients with metastatic papillary renal cell carcinoma (PRCC), a form of kidney cancer. The data from the S1500 trial (also called “PAPMET”), which was designed and managed by SWOG Cancer Research Network, will be presented on Saturday, February 13
th during the Oral Abstract Session: Renal Cell Cancer at 10:00 – 11:15 a.m. PT at the 2021 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU), which is being held virtually, February 11-13, 2021. The findings will be simultaneously published in
The Lancet.
“This is the first randomized trial specific to metastatic papillary renal cell carcinoma to show a clinically and statistically significant benefit with a targeted therapy, CABOMETYX, over an existing standard of care,” said Dr. Sumanta Pal, Clinical Professor and Co-Director of the Kidney Cancer Program, City of H